Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03954743
Other study ID # 208236
Secondary ID 2018-001986-18
Status Completed
Phase Phase 3
First received
Last updated
Start date July 19, 2019
Est. completion date November 30, 2020

Study information

Verified date February 2022
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to complete the total safety database size for GlaxoSmithKline Biologicals' (GSK's) human rotavirus (HRV) vaccine across the Porcine circovirus (PCV)-free development plan. This study used a purposely selected lot for PCV-free liquid HRV vaccine that is in the upper range of the usual release potencies. The PCV-free liquid HRV vaccine lots used were stored frozen in order to keep the titer stable until administration during the study. As the liquid formulation of GSK's HRV vaccine is not licensed in the US, the lyophilized formulation of the vaccine was used as a control in all phase III studies as part of the PCV-free development plan.


Recruitment information / eligibility

Status Completed
Enrollment 1351
Est. completion date November 30, 2020
Est. primary completion date November 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Weeks to 12 Weeks
Eligibility Inclusion Criteria: All subjects must satisfy all the following criteria at study entry: - Subjects' parent(s)/LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits). - Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performance of any study specific procedure. - Healthy subjects as established by medical history and clinical examination before entering into the study. - A male or female between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination. Exclusion Criteria: Medical conditions - Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for Intussusception (IS). - Very prematurely born infants (born =28 weeks of gestation). - History of IS. - Family history of congenital or hereditary immunodeficiency. - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). - Hypersensitivity to latex. - Major congenital defects or serious chronic illness, as assessed by the investigator. - Previous confirmed occurrence of Rotavirus Gastroenteritis (RV GE). - History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines. - History of Severe combined immunodeficiency (SCID). Prior/Concomitant therapy - Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study vaccines during the period starting 30 days before the first dose of study vaccines (Day -29 to Day 1), or planned use during the study period. - Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of study vaccine administration, with the exception of the inactivated influenza vaccine, which is allowed at any time during the study, and other licensed routine childhood vaccinations. - Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab). - Administration of immunoglobulins and/or any blood products from birth or planned administration during the study period. - Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone =0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed. - Previous vaccination against RV. Prior/Concurrent clinical study experience - Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or medical device). Other exclusions • Child in care.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine
2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
Lyophilized formulation of GSK's oral live attenuated HRV vaccine
2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.

Locations

Country Name City State
Canada GSK Investigational Site Brampton Ontario
Canada GSK Investigational Site Calgary Alberta
Canada GSK Investigational Site Halifax Nova Scotia
Canada GSK Investigational Site London Ontario
Canada GSK Investigational Site Montreal Quebec
Canada GSK Investigational Site Québec
Canada GSK Investigational Site Sarnia Ontario
Canada GSK Investigational Site Surrey British Columbia
Canada GSK Investigational Site Truro Nova Scotia
Hong Kong GSK Investigational Site Pokfulam
Hong Kong GSK Investigational Site Shatin
Taiwan GSK Investigational Site Changhua
Taiwan GSK Investigational Site Kaohsiung City
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Taipei
Turkey GSK Investigational Site Eskisehir
Turkey GSK Investigational Site Izmir
Turkey GSK Investigational Site Kayseri
United States GSK Investigational Site Bingham Farms Michigan
United States GSK Investigational Site Birmingham Alabama
United States GSK Investigational Site Charlottesville Virginia
United States GSK Investigational Site Cincinnati Ohio
United States GSK Investigational Site Colorado Springs Colorado
United States GSK Investigational Site Corvallis Oregon
United States GSK Investigational Site Draper Utah
United States GSK Investigational Site East Orange New Jersey
United States GSK Investigational Site Fairfield Ohio
United States GSK Investigational Site Fall River Massachusetts
United States GSK Investigational Site Frederick Maryland
United States GSK Investigational Site Lincoln Nebraska
United States GSK Investigational Site Lincoln Nebraska
United States GSK Investigational Site Lincoln Nebraska
United States GSK Investigational Site Louisville Kentucky
United States GSK Investigational Site Murray Utah
United States GSK Investigational Site Orem Utah
United States GSK Investigational Site South Jordan Utah
United States GSK Investigational Site Syracuse New York

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Canada,  Hong Kong,  Taiwan,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Any Solicited General Adverse Events (AEs) After the First Vaccination Assessed solicited general AEs were fever (defined as temperature = 38.0°C/100.4°F, the preferred location for measuring temperature in this study being the oral cavity, the axilla and the rectum), irritability/fussiness, diarrhea (defined as passage of three or more looser than normal stools within a day), vomiting (defined as one or more episodes of forceful emptying of partially digested stomach contents =1 hour after feeding within a day), loss of appetite and cough/runny nose. Any = occurrence of AE regardless of intensity grade or relation to study vaccination. During the 8-day follow-up period after the first vaccination (vaccines administered at Day 1)
Primary Number of Subjects With Any Solicited General Adverse Events (AEs) After the Second Vaccination Assessed solicited general AEs were fever (defined as temperature = 38.0°C/100.4°F, the preferred location for measuring temperature in this study being the oral cavity, the axilla and the rectum), irritability/fussiness, diarrhea (defined as passage of three or more looser than normal stools within a day), vomiting (defined as one or more episodes of forceful emptying of partially digested stomach contents =1 hour after feeding within a day), loss of appetite and cough/runny nose. Any = occurrence of AE regardless of intensity grade or relation to study vaccination. During the 8-day follow-up period after the second vaccination (vaccines administered at Month 1 or Month 2)
Primary Number of Subjects With Any Unsolicited AEs An unsolicited AE is defined as any untoward medical occurrence in a clinical study subject, temporally associated with the use of a study treatment, whether or not considered related to the study treatment, and reported in addition to those solicited during the clinical study and any 'solicited' AE with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of AE regardless of intensity grade or relation to study vaccination. During the 31-day follow-up period across doses (vaccines administered at Day 1 and at Month 1 or Month 2)
Primary Number of Subjects With Any Serious Adverse Events (SAEs) An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization and/or results in disability/incapacity. Any = occurrence of SAE regardless of intensity grade or relation to study vaccination. Throughout the study period (from Day 1 up to Month 7 or Month 8)
See also
  Status Clinical Trial Phase
Completed NCT01435967 - Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™ N/A
Completed NCT00370318 - Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines Phase 3
Completed NCT00345956 - To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam) Phase 3
Completed NCT00140686 - To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines Phase 3
Completed NCT00383903 - Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa Phase 2
Completed NCT00750893 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
Completed NCT00533507 - Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age Phase 3
Completed NCT00363545 - To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants) Phase 3
Completed NCT02914184 - Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks Phase 3
Completed NCT00489567 - Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden N/A
Completed NCT01733862 - Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis
Completed NCT00779779 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
Completed NCT00382772 - A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine). Phase 3
Completed NCT00729001 - Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants. Phase 2
Completed NCT00353366 - To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
Completed NCT01198769 - Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth. Phase 4
Completed NCT00385320 - Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months Phase 2
Completed NCT00432380 - A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants. Phase 2
Completed NCT01563159 - Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011 N/A
Completed NCT01339221 - Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium N/A